Clinical Trial Update: Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a recombinant multivalent HPV vaccine (types 6,11,16,18,31,33,45,52,58) for efficacy, immunogenicity, and safety; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Cervical Intraepithelial Neoplasia
• Genital Warts

Drugs mentioned

• Recombinant HPV vaccine (multitype, E. coli expression) (Human papillomavirus vaccine, recombinant, multivalent)

Snippet

Sponsor: Xiamen University | Conditions: Cervical Intraepithelial Neoplasia, Cervical Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING